{"id":60909,"date":"2026-04-14T17:02:08","date_gmt":"2026-04-14T17:02:08","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/60909\/"},"modified":"2026-04-14T17:02:08","modified_gmt":"2026-04-14T17:02:08","slug":"move-over-novo-nordisk-this-small-company-study-flags-edge-in-fatty-liver-drug-hoth-therapeutics-nas","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/60909\/","title":{"rendered":"Move Over Novo Nordisk &#8211; This Small Company Study Flags Edge In Fatty Liver Drug &#8211; Hoth Therapeutics (NAS"},"content":{"rendered":"<p>Hoth Therapeutics Candidate Shows Impact On Fat Production And Metabolism<\/p>\n<p class=\"block core-block\">The HT-VA study demonstrated that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) significantly reduces fat production and enhances fat metabolism at the genetic level, positioning it as a unique therapeutic <a target=\"_blank\" href=\"https:\/\/www.benzinga.com\/topic\/weight-loss\" rel=\"noreferrer noopener nofollow\">option for MAFLD and obesity<\/a>.<\/p>\n<p class=\"block core-block\">Hoth Therapeutics is a clinical-stage biopharmaceutical company.<\/p>\n<p class=\"block core-block\">The data show statistically significant modulation of genes linked to hepatic fat dynamics, positioning GDNF as a differentiated approach targeting underlying drivers of fatty liver disease and metabolic dysfunction.<\/p>\n<p>Strategic Implications For MAFLD And Obesity MarketsNext Steps In Development And Partnerships<br \/>\nAdvance into additional preclinical validation studies.<\/p>\n<p>Assess clinical development pathways in metabolic and liver diseases.<\/p>\n<p>Pursue partnerships to accelerate development and commercialization.<\/p>\n<p class=\"block core-block\">HOTH Stock Price Activity: Hoth Therapeutics shares were up 42.02% at $0.729 at the time of publication on Tuesday, according to <a href=\"https:\/\/benzinga.com\/services\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Benzinga Pro data<\/a>.<\/p>\n<p class=\"block core-block\">Image via Shutterstock<\/p>\n<p><a class=\"text-sm my-4\" href=\"https:\/\/www.benzinga.com\/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n<p class=\"copyright\">\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n<p class=\"block core-block\">To add Benzinga News as your preferred source on Google, <a href=\"https:\/\/google.com\/preferences\/source?q=https%3A%2F%2Fwww.benzinga.com\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Hoth Therapeutics Candidate Shows Impact On Fat Production And Metabolism The HT-VA study demonstrated that parenteral GDNF (Glial&hellip;\n","protected":false},"author":2,"featured_media":60910,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2089,2092,2088,33568,5813,2093,2084,272,352,33569,2096,2100],"class_list":{"0":"post-60909","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-movers","12":"tag-category-news","13":"tag-category-penny-stocks","14":"tag-category-top-stories","15":"tag-category-trading-ideas","16":"tag-cms-wordpress","17":"tag-novo-nordisk","18":"tag-pageisbzpro-bz","19":"tag-symbol-hoth","20":"tag-symbol-nvo","21":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116404141777183111","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/60909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=60909"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/60909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/60910"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=60909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=60909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=60909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}